Who are Synera(TM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levobupivacaine 0,5%, Liposome bupivacaine, Intravenous Lidocaine infusion + Standard Anesthesia, IV lignocaine bolus and infusion, Anesthetics, Local, Fentanyl and bupivacaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/synera-tm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Synera(TM) — Competitive Intelligence Brief

Synera(TM) (Synera(TM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical local anesthetic. Area: Dermatology/Pain Management.

marketed Topical local anesthetic Voltage-gated sodium channels Dermatology/Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Synera(TM) (Synera(TM)) — IWK Health Centre. Synera is a topical anesthetic patch that combines lidocaine and tetracaine to provide rapid local anesthesia through transdermal delivery.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Synera(TM) TARGET	Synera(TM)	IWK Health Centre	marketed	Topical local anesthetic	Voltage-gated sodium channels
Levobupivacaine 0,5%	Levobupivacaine 0,5%	ASST Gaetano Pini-CTO	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Liposome bupivacaine	Liposome bupivacaine	Catherine Vandepitte, M.D.	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Intravenous Lidocaine infusion + Standard Anesthesia	Intravenous Lidocaine infusion + Standard Anesthesia	Instituto Mexicano del Seguro Social	marketed	Local anesthetic (sodium channel blocker)	Voltage-gated sodium channels
IV lignocaine bolus and infusion	IV lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic; Class IB antiarrhythmic agent	Voltage-gated sodium channels
Anesthetics, Local	Anesthetics, Local	University of Alberta	marketed	Local anesthetic	Voltage-gated sodium channels
Fentanyl and bupivacaine	Fentanyl and bupivacaine	Hospital Central Dr. Luis Ortega	marketed	Opioid analgesic combined with local anesthetic	Mu opioid receptor (fentanyl); voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical local anesthetic class)

American University of Beirut Medical Center · 1 drug in this class
Brown, Theodore R., M.D., MPH · 1 drug in this class
Eugene Y Rhee, MD · 1 drug in this class
IWK Health Centre · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Synera(TM) — Competitive Intelligence Brief. https://druglandscape.com/ci/synera-tm. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab